Treatments for rare diseases face unique challenges in getting to market. Rare diseases are hard to diagnose, challenging to study and difficult to treat. Patients need access to effective therapies, but healthcare budgets are squeezed. The way that value is defined, measured and interpreted in rare diseases is complex and changing all the time.
To be successful in this environment, companies developing rare disease treatments need a specialised approach to prepare for pricing and reimbursement negotiations globally.
At Dolon, we specialise in strategic pricing and market access for rare and severe diseases.
We have up-to-the-minute knowledge of reimbursement pathways and payer requirements. We have insight into the way decisions are being made and visibility into how the environment is evolving. We help our clients think strategically about market access, and prepare for pricing and reimbursement negotiations, by providing services in the following areas:
Talk to us about how we can deliver intelligent value strategies for your specialist portfolio.
